A Study of IMC-1121B (Ramucirumab) in Colorectal Cancer

NCT00862784 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

BIOLOGICAL: IMC-1121B (ramucirumab)
DRUG: Oxaliplatin
DRUG: Folinic acid
DRUG: 5-FU
DRUG: 5-FU

Sponsor

Eli Lilly and Company